BioPorto Collaborates with Top Children's Hospitals
BioPorto A/S is thrilled to announce its partnership with nine of the top ten children’s hospitals in the United States, as recognized by US News & World Report. As an innovative in vitro diagnostics company, BioPorto focuses on empowering healthcare professionals with tools that enhance the early detection of Acute Kidney Injury (AKI).
The Significance of the Partnership
The recent rankings released by respected publications highlight the remarkable achievements of these pediatric hospitals. Institutions such as Boston Children's Hospital, Children's Hospital Colorado, and Children's Hospital Los Angeles are among those leading the charge in pediatric healthcare excellence. The hospitals receiving the prestigious “Best” designation excel in numerous areas including clinical outcomes and the quality of resources dedicated to patient care.
Impact of NGAL Testing
Nine of these distinguished hospitals have integrated BioPorto’s neutrophil gelatinase-associated lipocalin (NGAL) tests into their clinical research settings. These tests play a pivotal role in assessing the risk of AKI, particularly for critically ill pediatric patients. With the backing of such reputable hospitals, BioPorto aims to redefine AKI risk assessment and facilitate better care strategies for vulnerable patients.
Expert Insights on NGAL
Jennifer Zonderman, the Senior Vice President of Global Marketing at BioPorto, expressed her enthusiasm regarding this partnership, stating, "We are very encouraged to see our partners on the list of the best children’s hospitals in the US. Their expertise and commitment to providing the best possible care for their patients is indeed well established and well earned." This statement underscores the strong alliance between BioPorto and leading medical institutions.
Benefits of Early AKI Detection
BioPorto's ProNephro AKI™ (NGAL) has received clearance from the US Food and Drug Administration (FDA) for use in patients aged three months to 21 years. Recognized for its remarkable capability to detect kidney damage early, NGAL can identify potential AKI cases days before traditional serum creatinine tests. This proactive approach could drastically change the outcome for many young patients in critical care.
According to recent surveys, an overwhelming majority of healthcare professionals managing critically ill patients—96%, in fact—believe that early identification of AKI can lead to significantly improved patient outcomes. The ability of NGAL levels to rise within two hours of kidney injury is invaluable, as it allows for timely interventions that can prevent further complications.
Continuing Growth and Innovation
BioPorto is committed to establishing a robust framework for future growth regarding the utilization of NGAL testing products. By partnering with hospitals leading clinical change across the globe, BioPorto aims to drive a paradigm shift in how AKI is diagnosed and monitored.
Future Directions with NGAL
In partnership with top children's hospitals, BioPorto envisions a future where NGAL-based damage biomarkers become the standard in clinical settings. The effort to address gaps in AKI diagnosis will not only lead to improved patient care but also set new standards in pediatric healthcare practices.
Frequently Asked Questions
What is the NGAL test?
The NGAL test measures levels of neutrophil gelatinase-associated lipocalin, a biomarker indicative of kidney damage, allowing for earlier detection of Acute Kidney Injury.
Which children's hospitals partner with BioPorto?
BioPorto has partnered with nine of the top ten children's hospitals in the United States, including distinguished institutions such as Boston Children's Hospital and Children's National Hospital.
How does early detection of AKI impact patient outcomes?
Early detection of AKI through NGAL testing enables timely interventions, which can significantly improve recovery rates and reduce complications in critically ill patients.
What age group is the ProNephro AKI™ (NGAL) test approved for?
The ProNephro AKI™ (NGAL) test is approved for use in patients ranging from three months to 21 years of age.
How does BioPorto plan to expand its NGAL testing?
BioPorto aims to expand NGAL testing by partnering with leading healthcare institutions worldwide to promote the paradigm shift towards using NGAL as a standard diagnostic tool for kidney injury.
